Ellume

Ellume is an Australian biotechnology company founded in 2009, based in Brisbane. The company specializes in digital diagnostic solutions for infectious diseases, focusing on both home and clinical use. Ellume aims to enhance global health by providing fast, accurate, and accessible testing, enabling individuals and healthcare systems to make informed decisions through reliable results. The company utilizes advanced technology that combines optics, electronics, biological components, and software. Their innovative approach includes the use of fluorescent nanoparticles to detect disease markers with high sensitivity. Ellume's flagship product was the first over-the-counter, at-home COVID-19 test to receive Emergency Use Authorization from the U.S. FDA. This test allows for rapid self-diagnosis using a nasal swab and a Bluetooth-connected analyzer that sends results to a smartphone. Ellume also offers home-based tests for influenza and connected digital diagnostics that facilitate easy result interpretation and data sharing. With manufacturing capabilities in the United States, Ellume serves consumers, healthcare professionals, large employers, and public health agencies, all while striving to improve health outcomes and pandemic preparedness globally.

• Employees 43
• Founded 2010
• Total Funding $5000000